Cryopreservation in Hybridoma Production

  • L. de Leij
  • E. Schwander
  • T. H. The
Part of the Contemporary Biomedicine book series (CB, volume 7)


Hybridomas are normally made by random fusion of immune spleen cells with myeloma cells. Selection of hybridomas that produce antibodies with the specificity one is looking for only occurs after establishment and growth of all obtained hybridomas. Depending on the purity and nature of the antigen used for immunization, a variable number of different screening tests must be performed before the specificities of the obtained hybridomas are defined. Since hybridomas grow quickly it is generally accepted that at least the first screening tests should be performed rapidly. This poses a problem when time-consuming screening protocols are deemed necessary. Furthermore the propagation and eventual preservation of large numbers of hybridoma cultures, which are likely to include many useless ones, involves much labor, considerable costs, and infection hazards. To cope with the first problem and to minimize the latter, cryopreservation of hybridomas can be applied. The technique to cryopreserve tissue cultured cells was developed some decades ago (1,2). Depending on their tissue origin, cultured cells proved to be susceptible to cryopreservation to varying degrees (3). Cells of the hematopoietic lineage are especially vulnerable.


Spleen Cell Myeloma Cell Freezing Medium Newborn Calf Serum Immune Spleen Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schrerer W. F. and Hoogasisu A. C.: 1954. Preservation at subzero temperature of mouse fibroblasts (strain L) and human epithelial cells (strain HeLa). Proc. Soc. Exp. Biol. Med. 87: 480–487.Google Scholar
  2. 2.
    Hanschka T.S. Mitchell J.T and Niederpruem D. J.: 1959. A reliable frozen tissue bank: Viability and stability of 82 neoplastic and normal cell types after prolonged storage at -78°C. Cancer Res. 19: 643–653.Google Scholar
  3. 3.
    Meryman H.T.: 1963. Preservation of living cells. Fed. Proc. 22: 81–89.PubMedGoogle Scholar
  4. 4.
    Mazur P. and Rajotte R. V.: 1981. Permeability of the 17-day fetal rat pancreas to glycerol and dimethylsulfoxide. Cryobiology 18: 1–10.PubMedCrossRefGoogle Scholar
  5. 5.
    Meryman H. T.: 1956. Mechanism of freezing in living cells and tissues. Science 124: 515–521.PubMedCrossRefGoogle Scholar
  6. 6.
    Bois M. J. G.J., Schellekens P. T. A., de Wit J. J. F. M., and Eijsvoogel V. P.: 1976. In vitro reactivity of human lymphocytes after cryopreservation using a programmed cooling device. Scand.]. Immunol. 5: 17–22.CrossRefGoogle Scholar
  7. 7.
    Wells D. E. and Price P. J.: 1983. Simple rapid methods for freezing hybridomas in 96-well microculture plates. J. Immunol. Meth. 59: 49–52.CrossRefGoogle Scholar
  8. 8.
    De Leij L., Poppema S., and The T. H.: 1983. Cryopreservation of newly formed hybridomas. J. Immunol. Meth. 62: 69–72.CrossRefGoogle Scholar
  9. 9.
    Kennett, R. H.: 1980. Fusion by centrifugation of cells suspended in polyethylene glycol, In Monoclonal Antibodies ( R. H. Kennett and T. J. McKearn, eds.) New York, Plenum.Google Scholar
  10. 10.
    De Leij L., Poppema, S., Klein Nulend J., Ter Haar J. G., Schwander E., and The T. H.: 1984. Immunoperoxidase staining as a first screening assay in the preparation of monoclonal antibodies directed against SCLC. Eur. J. Cancer Clin. Oncol. 20: 123–128PubMedCrossRefGoogle Scholar

Copyright information

© The Humana Press Inc. 1987

Authors and Affiliations

  • L. de Leij
  • E. Schwander
  • T. H. The

There are no affiliations available

Personalised recommendations